CL2015003591A1 - Obtención de un ligando terapéutico mejorado - Google Patents

Obtención de un ligando terapéutico mejorado

Info

Publication number
CL2015003591A1
CL2015003591A1 CL2015003591A CL2015003591A CL2015003591A1 CL 2015003591 A1 CL2015003591 A1 CL 2015003591A1 CL 2015003591 A CL2015003591 A CL 2015003591A CL 2015003591 A CL2015003591 A CL 2015003591A CL 2015003591 A1 CL2015003591 A1 CL 2015003591A1
Authority
CL
Chile
Prior art keywords
obtaining
improved therapeutic
therapeutic ligand
union
beginning
Prior art date
Application number
CL2015003591A
Other languages
English (en)
Inventor
Jiye Shi
Terence Seward Baker
Alastair David Griffiths Lawson
Xiaofeng Liu
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2015003591A1 publication Critical patent/CL2015003591A1/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/90—Programming languages; Computing architectures; Database systems; Data warehousing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Computing Systems (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Software Systems (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

MÉTODO DE DISEÑO DE UN LIGANDO AB INITIO QUE SE UNE A UN SITIO DE UNIÓN DE UN AGENTE TERAPÉUTICO, EL CUAL COMPRENDE INDENTIFICAR REGIONES FAVORECIDAS ADYACENTES AL SITIO DE UNIÓN Y MODIFICAR EL LIGANDO PARA MEJORAR LA UNIÓN.
CL2015003591A 2013-06-13 2015-12-10 Obtención de un ligando terapéutico mejorado CL2015003591A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1310544.0A GB201310544D0 (en) 2013-06-13 2013-06-13 Obtaining an improved therapeutic ligand

Publications (1)

Publication Number Publication Date
CL2015003591A1 true CL2015003591A1 (es) 2016-08-05

Family

ID=48914497

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003591A CL2015003591A1 (es) 2013-06-13 2015-12-10 Obtención de un ligando terapéutico mejorado

Country Status (15)

Country Link
US (2) US20160125124A1 (es)
EP (1) EP3008648B1 (es)
JP (1) JP6484612B2 (es)
KR (1) KR20160019504A (es)
CN (1) CN105308602B (es)
AU (1) AU2014280055A1 (es)
BR (1) BR112015031171A2 (es)
CA (1) CA2914726A1 (es)
CL (1) CL2015003591A1 (es)
GB (1) GB201310544D0 (es)
HK (1) HK1218579A1 (es)
MX (1) MX2015016822A (es)
RU (1) RU2016100234A (es)
SG (2) SG10201707917UA (es)
WO (1) WO2014198951A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022019047A2 (pt) 2020-03-27 2022-11-01 UCB Biopharma SRL Peptídeos de domínio knob autônomos
CN113380320B (zh) * 2021-07-01 2022-03-15 中国海洋大学 基于阳性化合物残基贡献相似度的分子对接结果筛选方法
CN115708166A (zh) * 2021-08-20 2023-02-21 北京望石智慧科技有限公司 一种药物分子设计方法、装置、电子设备及存储介质
CN114530215B (zh) * 2022-02-18 2023-03-28 北京有竹居网络技术有限公司 设计配体分子的方法和装置
CN115171774A (zh) * 2022-05-17 2022-10-11 慧壹科技(上海)有限公司 一种抗体/大分子药物的亲和力改造系统和方法
WO2025008323A1 (en) 2023-07-03 2025-01-09 UCB Biopharma SRL Engineered aav capsid proteins
GB202314896D0 (en) 2023-09-28 2023-11-15 UCB Biopharma SRL Knob domain proteins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5642292A (en) 1992-03-27 1997-06-24 Akiko Itai Methods for searching stable docking models of biopolymer-ligand molecule complex
GB0011818D0 (en) * 2000-05-16 2000-07-05 Inpharmatica Ltd Lead molecule generation
US20020025535A1 (en) 2000-06-15 2002-02-28 Diller David J. Prioritization of combinatorial library screening
AU2001279973A1 (en) 2000-08-21 2002-03-04 Ribotargets Limited Computer-based modelling of ligand/receptor structures
JP2004511803A (ja) * 2000-10-16 2004-04-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド バニロイド受容体についての改良リガンド結合アッセイ
WO2002059264A2 (en) * 2000-12-29 2002-08-01 Bio-Technology General Corp. Specific human antibodies for selective cancer therapy
US20030148391A1 (en) * 2002-01-24 2003-08-07 Salafsky Joshua S. Method using a nonlinear optical technique for detection of interactions involving a conformational change
US20040229290A1 (en) 2003-05-07 2004-11-18 Duke University Protein design for receptor-ligand recognition and binding
US20060105390A1 (en) * 2003-10-29 2006-05-18 Yi Zhang Method of characterizing heterogeneity in receptor-ligand interactions and related method of assay signal histogram transformation
JP2005181104A (ja) * 2003-12-19 2005-07-07 Hitachi Ltd 高精度ドッキングスコアリング方法
JP4719223B2 (ja) 2005-03-11 2011-07-06 シュレディンガー エルエルシー 結合親和性を推定するための予測的スコア関数
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
US20090018777A1 (en) * 2007-05-24 2009-01-15 Peter Hrnciar Systems and Methods for Predicitng Ligand-Protein Binding Interactions
CN101855392A (zh) * 2007-11-12 2010-10-06 电子虚拟生物科技株式会社 虚拟筛选装置及虚拟筛选方法
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
WO2010110288A1 (ja) * 2009-03-24 2010-09-30 株式会社カネカ 免疫グロブリンに親和性を有するタンパク質および免疫グロブリン結合性アフィニティーリガンド
US9023876B2 (en) * 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
SG10201510762YA (en) 2011-01-14 2016-01-28 Ucb Pharma Sa Antibody molecules which bind il-17a and il-17f

Also Published As

Publication number Publication date
KR20160019504A (ko) 2016-02-19
US20210005277A1 (en) 2021-01-07
AU2014280055A1 (en) 2016-01-28
JP6484612B2 (ja) 2019-03-13
RU2016100234A3 (es) 2018-03-23
BR112015031171A2 (pt) 2017-07-25
EP3008648A2 (en) 2016-04-20
US20160125124A1 (en) 2016-05-05
SG11201510084TA (en) 2016-01-28
EP3008648B1 (en) 2023-05-10
CN105308602A (zh) 2016-02-03
WO2014198951A2 (en) 2014-12-18
WO2014198951A3 (en) 2015-08-27
SG10201707917UA (en) 2017-10-30
CA2914726A1 (en) 2014-12-18
US11942188B2 (en) 2024-03-26
RU2016100234A (ru) 2018-02-06
JP2016527481A (ja) 2016-09-08
HK1218579A1 (zh) 2017-02-24
MX2015016822A (es) 2016-04-13
CN105308602B (zh) 2019-09-27
GB201310544D0 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
CL2015003591A1 (es) Obtención de un ligando terapéutico mejorado
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
BR112016001611A2 (pt) Anticorpos multiespecíficos, anticorpos ativáveis multiespecíficos e métodos de utilização dos mesmos
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
MX370807B (es) Anticuerpos que se unen a axl.
MX2016001236A (es) Anticuerpos anti-fgfr2iiib afucosilados.
DK3498725T3 (da) 19-nor c3,3-desubstitueret c21-n-pyrazolyl steroid til anvendelse i terapi
DK3027208T3 (da) Cancerdiagnose og -terapi, der involverer cancerstamceller
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
UY36075A (es) Derivados de tubulisina
HUE053787T2 (hu) Viszkozitást javító súrlódáscsökkentõk
CL2015002116A1 (es) Administración de compuesto anti-activin-a a un sujeto
PL3080395T3 (pl) Sposób budowy przejść krzyżowych w tunelach dwururowych
AR096183A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
SV2019005822A (es) Metodos para tratar el cáncer de próstata
CL2016000770A1 (es) Anticuerpos conjugados contra ly75 para el tratamiento del cáncer
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
EP3031340A4 (en) SOLE FOR SHOES AND SHOES
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
DE112014002764A5 (de) Schuh und Schuhset
AR097668A1 (es) Colorante-polímero
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
UY35823A (es) Profármacos de antagonista de nmda
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.